Actively Recruiting
Molecular Signatures of TMS Response in Treatment-Resistant Depression
Led by Gulhane Training and Research Hospital · Updated on 2025-06-26
55
Participants Needed
2
Research Sites
102 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD). This study aims to identify biomarkers that predict TMS treatment response in TRD, provide insights into the neurobiological mechanisms underlying TMS efficacy, and contribute to personalized treatment strategies. By establishing proteomic and metabolomic signatures, this research seeks to enhance clinical decision-making, reduce healthcare costs, and improve patient outcomes in TRD. The findings will align with the precision medicine movement in psychiatry, advancing biomarker-driven therapeutic approaches for treatment-resistant depression.
CONDITIONS
Official Title
Molecular Signatures of TMS Response in Treatment-Resistant Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Major Depressive Disorder (MDD) according to DSM-5-TR criteria
- Inadequate response to at least two antidepressants or anti-obsessive agents at therapeutic doses and durations
- Symptoms not better explained by metabolic or organic medical conditions
- No epileptic activity on routine EEG before starting TMS
- Normal thyroid hormone levels and no significant vitamin deficiencies or elevated inflammatory markers in pre-TMS lab tests
- No history or evidence of hearing loss, or evaluated by an otolaryngologist if present
- Age 18 years or older
- Ability to provide written informed consent
You will not qualify if you...
- Any contraindications to TMS identified in the pre-TMS risk assessment
- Epileptic focus detected on pre-TMS EEG
- History of significant head trauma, loss of consciousness, or brain surgery
- Presence of metal implants or foreign bodies incompatible with TMS (e.g., aneurysm clips, surgical clamps, metallic fragments)
- Abnormal thyroid hormone levels in pre-TMS labs
- Elevated inflammatory markers (e.g., CRP) in pre-TMS bloodwork
- Vitamin deficiencies linked to cognitive impairment (e.g., B12, folate) in pre-TMS labs
- Electrolyte imbalances in pre-TMS blood testing
- History of psychotic disorder or bipolar I/II disorder
- History of substance-induced psychosis or bipolar disorder
- Current or past substance use disorder unless abstinent for at least 12 months (excluding alcohol)
- Voluntary discontinuation of TMS during treatment
- Serious adverse events or unexpected clinical conditions requiring TMS discontinuation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Gulhane Training and Research Hospital
Ankara, Ankara, Turkey (Türkiye), 06000
Actively Recruiting
2
Gulhane Training and Research Hospital
Ankara, Ankara, Turkey (Türkiye), 06300
Actively Recruiting
Research Team
B
BEYAZIT GARİP, Medical Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here